Molecular Partners AG
MOLN
Hisse Senetlerindeki Sıralama
#19819
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Hisse Fiyatı
$3.58
Piyasa Değeri
$137.13M
Değişim (1 gün)
-2.96%
Değişim (1 yıl)
0.33%
Ülke
CH
Ticaret Molecular Partners AG (MOLN)
Kategori
Healthcare
Molecular Partners AG (MOLN) için P/B oranı
2026 itibarıyla P/B oranı TTM: 0
Molecular Partners AG şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/B oranı 0 idi.
Molecular Partners AG için P/B oranı geçmişi 2013 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2025 | 1.57 | 61.23% |
| 2024 | 0.98 | 52.66% |
| 2023 | 0.64 | -24.87% |
| 2022 | 0.85 | -83.48% |
| 2021 | 5.15 | 6.44% |
| 2020 | 4.84 | -30.18% |
| 2019 | 6.93 | 64.05% |
| 2018 | 4.22 | -10.13% |
| 2017 | 4.70 | 25.99% |
| 2016 | 3.73 | -17.19% |
| 2015 | 4.51 | 93.64% |
| 2014 | 2.33 | -74.59% |
| 2013 | 9.16 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.4521 | - |
AU
|
|
| 6.3632 | - |
NL
|
|
| 3.2932 | - |
BE
|
